Progression of Human Renal Cell Carcinoma via Inhibition of RhoA-ROCK Axis by PARG1

Junichiro Miyazaki, Keiichi Ito, Tomonobu Fujita, Yuriko Matsuzaki, Takako Asano, Masamichi Hayakawa, Tomohiko Asano, Yutaka Kawakami

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Renal cell carcinoma (RCC) is the most lethal urological malignancy with high risk of recurrence; thus, new prognostic biomarkers are needed. In this study, a new RCC antigen, PTPL1 associated RhoGAP1 (PARG1), was identified by using serological identification of recombinant cDNA expression cloning with sera from RCC patients. PARG1 protein was found to be differentially expressed in RCC cells among patients. High PARG1 expression is significantly correlated with various clinicopathological factors relating to cancer cell proliferation and invasion, including G3 percentage (P = .0046), Ki-67 score (p expression is also correlated with high recurrence of N0M0 patients (P = .0084) and poor prognosis in RCC patients (P = .0345). Multivariate analysis has revealed that high PARG1 expression is an independent factor for recurrence (P = .0149) of N0M0 RCC patients. In in vitro studies, depletion of PARG1by siRNA in human RCC cell lines inhibited their proliferation through inducing G1 cell cycle arrest via upregulation of p53 and subsequent p21Cip1/Waf1, which are mediated by increased RhoA-ROCK activities. Similarly, PARG1 depletion cells inhibited invasion ability via increasing RhoA-ROCK activities in the RCC cell lines. Conversely, overexpression of PARG1 on human embryonic kidney cell line HEK293T promotes its cell proliferation and invasion. These results indicate that PARG1 plays crucial roles in progression of human RCC in increasing cell proliferation and invasion ability via inhibition of the RhoA-ROCK axis, and PARG1 is a poor prognostic marker, particularly for high recurrence of N0M0 RCC patients.

Original languageEnglish
Pages (from-to)142-152
Number of pages11
JournalTranslational Oncology
Volume10
Issue number2
DOIs
Publication statusPublished - 2017 Apr 1

Fingerprint

Renal Cell Carcinoma
Recurrence
Cell Proliferation
Cell Line
G1 Phase Cell Cycle Checkpoints
Small Interfering RNA
Organism Cloning
Neoplasms
Up-Regulation
Multivariate Analysis
Complementary DNA
Biomarkers
Kidney
Antigens
Serum

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Progression of Human Renal Cell Carcinoma via Inhibition of RhoA-ROCK Axis by PARG1. / Miyazaki, Junichiro; Ito, Keiichi; Fujita, Tomonobu; Matsuzaki, Yuriko; Asano, Takako; Hayakawa, Masamichi; Asano, Tomohiko; Kawakami, Yutaka.

In: Translational Oncology, Vol. 10, No. 2, 01.04.2017, p. 142-152.

Research output: Contribution to journalArticle

Miyazaki, J, Ito, K, Fujita, T, Matsuzaki, Y, Asano, T, Hayakawa, M, Asano, T & Kawakami, Y 2017, 'Progression of Human Renal Cell Carcinoma via Inhibition of RhoA-ROCK Axis by PARG1', Translational Oncology, vol. 10, no. 2, pp. 142-152. https://doi.org/10.1016/j.tranon.2016.12.004
Miyazaki, Junichiro ; Ito, Keiichi ; Fujita, Tomonobu ; Matsuzaki, Yuriko ; Asano, Takako ; Hayakawa, Masamichi ; Asano, Tomohiko ; Kawakami, Yutaka. / Progression of Human Renal Cell Carcinoma via Inhibition of RhoA-ROCK Axis by PARG1. In: Translational Oncology. 2017 ; Vol. 10, No. 2. pp. 142-152.
@article{7046c70b0820482e8ecb7e2d8aba3fff,
title = "Progression of Human Renal Cell Carcinoma via Inhibition of RhoA-ROCK Axis by PARG1",
abstract = "Renal cell carcinoma (RCC) is the most lethal urological malignancy with high risk of recurrence; thus, new prognostic biomarkers are needed. In this study, a new RCC antigen, PTPL1 associated RhoGAP1 (PARG1), was identified by using serological identification of recombinant cDNA expression cloning with sera from RCC patients. PARG1 protein was found to be differentially expressed in RCC cells among patients. High PARG1 expression is significantly correlated with various clinicopathological factors relating to cancer cell proliferation and invasion, including G3 percentage (P = .0046), Ki-67 score (p expression is also correlated with high recurrence of N0M0 patients (P = .0084) and poor prognosis in RCC patients (P = .0345). Multivariate analysis has revealed that high PARG1 expression is an independent factor for recurrence (P = .0149) of N0M0 RCC patients. In in vitro studies, depletion of PARG1by siRNA in human RCC cell lines inhibited their proliferation through inducing G1 cell cycle arrest via upregulation of p53 and subsequent p21Cip1/Waf1, which are mediated by increased RhoA-ROCK activities. Similarly, PARG1 depletion cells inhibited invasion ability via increasing RhoA-ROCK activities in the RCC cell lines. Conversely, overexpression of PARG1 on human embryonic kidney cell line HEK293T promotes its cell proliferation and invasion. These results indicate that PARG1 plays crucial roles in progression of human RCC in increasing cell proliferation and invasion ability via inhibition of the RhoA-ROCK axis, and PARG1 is a poor prognostic marker, particularly for high recurrence of N0M0 RCC patients.",
author = "Junichiro Miyazaki and Keiichi Ito and Tomonobu Fujita and Yuriko Matsuzaki and Takako Asano and Masamichi Hayakawa and Tomohiko Asano and Yutaka Kawakami",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.tranon.2016.12.004",
language = "English",
volume = "10",
pages = "142--152",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "2",

}

TY - JOUR

T1 - Progression of Human Renal Cell Carcinoma via Inhibition of RhoA-ROCK Axis by PARG1

AU - Miyazaki, Junichiro

AU - Ito, Keiichi

AU - Fujita, Tomonobu

AU - Matsuzaki, Yuriko

AU - Asano, Takako

AU - Hayakawa, Masamichi

AU - Asano, Tomohiko

AU - Kawakami, Yutaka

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Renal cell carcinoma (RCC) is the most lethal urological malignancy with high risk of recurrence; thus, new prognostic biomarkers are needed. In this study, a new RCC antigen, PTPL1 associated RhoGAP1 (PARG1), was identified by using serological identification of recombinant cDNA expression cloning with sera from RCC patients. PARG1 protein was found to be differentially expressed in RCC cells among patients. High PARG1 expression is significantly correlated with various clinicopathological factors relating to cancer cell proliferation and invasion, including G3 percentage (P = .0046), Ki-67 score (p expression is also correlated with high recurrence of N0M0 patients (P = .0084) and poor prognosis in RCC patients (P = .0345). Multivariate analysis has revealed that high PARG1 expression is an independent factor for recurrence (P = .0149) of N0M0 RCC patients. In in vitro studies, depletion of PARG1by siRNA in human RCC cell lines inhibited their proliferation through inducing G1 cell cycle arrest via upregulation of p53 and subsequent p21Cip1/Waf1, which are mediated by increased RhoA-ROCK activities. Similarly, PARG1 depletion cells inhibited invasion ability via increasing RhoA-ROCK activities in the RCC cell lines. Conversely, overexpression of PARG1 on human embryonic kidney cell line HEK293T promotes its cell proliferation and invasion. These results indicate that PARG1 plays crucial roles in progression of human RCC in increasing cell proliferation and invasion ability via inhibition of the RhoA-ROCK axis, and PARG1 is a poor prognostic marker, particularly for high recurrence of N0M0 RCC patients.

AB - Renal cell carcinoma (RCC) is the most lethal urological malignancy with high risk of recurrence; thus, new prognostic biomarkers are needed. In this study, a new RCC antigen, PTPL1 associated RhoGAP1 (PARG1), was identified by using serological identification of recombinant cDNA expression cloning with sera from RCC patients. PARG1 protein was found to be differentially expressed in RCC cells among patients. High PARG1 expression is significantly correlated with various clinicopathological factors relating to cancer cell proliferation and invasion, including G3 percentage (P = .0046), Ki-67 score (p expression is also correlated with high recurrence of N0M0 patients (P = .0084) and poor prognosis in RCC patients (P = .0345). Multivariate analysis has revealed that high PARG1 expression is an independent factor for recurrence (P = .0149) of N0M0 RCC patients. In in vitro studies, depletion of PARG1by siRNA in human RCC cell lines inhibited their proliferation through inducing G1 cell cycle arrest via upregulation of p53 and subsequent p21Cip1/Waf1, which are mediated by increased RhoA-ROCK activities. Similarly, PARG1 depletion cells inhibited invasion ability via increasing RhoA-ROCK activities in the RCC cell lines. Conversely, overexpression of PARG1 on human embryonic kidney cell line HEK293T promotes its cell proliferation and invasion. These results indicate that PARG1 plays crucial roles in progression of human RCC in increasing cell proliferation and invasion ability via inhibition of the RhoA-ROCK axis, and PARG1 is a poor prognostic marker, particularly for high recurrence of N0M0 RCC patients.

UR - http://www.scopus.com/inward/record.url?scp=85026425250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026425250&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2016.12.004

DO - 10.1016/j.tranon.2016.12.004

M3 - Article

AN - SCOPUS:85026425250

VL - 10

SP - 142

EP - 152

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 2

ER -